Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy-Reference-Cited by-同舟云学术

Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy

Published:2019-09-13 Issue:1 Volume:36 Page:9-15
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Oldenburg Johannes¹,Yan Songkai²,Maro Geraldine³,Krishnarajah Girishanthy²,Tiede Andreas⁴

Affiliation:

1. Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany;

2. CSL Behring, King of Prussia, PA, USA;

3. Adivo Associates, San Francisco, CA, USA;

4. Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2019.1662675

Reference19 articles.

1. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B

2. World Federation of Hemophilia [Internet]. Guidelines for the management of hemophilia; 2012 [cited 2019 Jun 14]. Available from: http://www1.wfh.org/publications/files/pdf-1472.pdf.

3. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

4. Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis

5. Effect of late prophylaxis in hemophilia on joint status: a randomized trial

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B;Haemophilia;2024-06-20

2. Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany;PharmacoEconomics - Open;2024-03-23

3. Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study;European Journal of Haematology;2024-01-15

4. Protein S antibody as an adjunct therapy for hemophilia B;Blood Advances;2024-01-12

5. Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic;Clinical Case Reports;2023-11-28